Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

F Caputo; K Skala; A Mirijello; A Ferrulli; H Walter; O Lesch; Giovanni Addolorato

doi:10.1007/s40263-014-0183-1

Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

F Caputo
, K Skala
, A Mirijello
, A Ferrulli
, H Walter
, O Lesch
, Giovanni Addolorato^*

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

17 Citazioni (Scopus)

Abstract

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

Lingua originale	Inglese
pagine (da-a)	743-752
Numero di pagine	10
Rivista	CNS Drugs
Volume	28
Numero di pubblicazione	8
DOI	https://doi.org/10.1007/s40263-014-0183-1
Stato di pubblicazione	Pubblicato - 2014

All Science Journal Classification (ASJC) codes

Neurologia (clinica)
Psichiatria e Salute Mentale
Farmacologia (medica)

Keywords

alcohol withdrawal syndrome
sodium oxybate

Accesso al documento

10.1007/s40263-014-0183-1

Altri file e collegamenti

Cita questo

@article{18a7a90d30f046b496964d953e3e02d2,

title = "Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial",

abstract = "Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.",

keywords = "alcohol withdrawal syndrome, sodium oxybate, alcohol withdrawal syndrome, sodium oxybate",

author = "F Caputo and K Skala and A Mirijello and A Ferrulli and H Walter and O Lesch and Giovanni Addolorato",

year = "2014",

doi = "10.1007/s40263-014-0183-1",

language = "English",

volume = "28",

pages = "743--752",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Adis",

number = "8",

}

TY - JOUR

T1 - Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

AU - Caputo, F

AU - Skala, K

AU - Mirijello, A

AU - Ferrulli, A

AU - Walter, H

AU - Lesch, O

AU - Addolorato, Giovanni

PY - 2014

Y1 - 2014

N2 - Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

AB - Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

KW - alcohol withdrawal syndrome

KW - sodium oxybate

KW - alcohol withdrawal syndrome

KW - sodium oxybate

UR - https://publicatt.unicatt.it/handle/10807/60505

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84905560288&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84905560288&origin=inward

U2 - 10.1007/s40263-014-0183-1

DO - 10.1007/s40263-014-0183-1

M3 - Article

SN - 1172-7047

VL - 28

SP - 743

EP - 752

JO - CNS Drugs

JF - CNS Drugs

IS - 8

ER -

Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo